Market Overview

UPDATE: JMP Securities Reiterates on Depomed Following Acquisition of Migraine Asset

Related DEPO
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape

In a report published Wednesday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Depomed (NASDAQ: DEPO), and raised the price target from $10.00 to $11.00.

In the report, JMP Securities noted, “Acquisition of migraine asset makes strategic and financial sense; reiterate Market Outperform rating and increasing price target from $10 to $11 on Depomed, Inc. Yesterday, Depomed announced the acquisition of CAMBIA, a formulation of the NSAID diclofenac approved for the treatment of migraine. Depomed will pay Nautilus Neurosciences $48.7MM upfront to acquire the product, representing ~2.7x the current annualized sales run rate, and stated that the transaction is expected to be immediately accretive. We view the product as a good strategic fit for Depomed, leveraging the company's established neurology-focused sales organization. We have updated our model to include sales of CAMBIA, which increases our 2014 and 2015 revenue estimates by 23% and 21%, respectively. We are increasing our price target from $10 to $11, now including CAMBIA in our sum-of-the-parts NPV analysis.”

Depomed closed on Tuesday at $8.34.

Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (DEPO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional